EichorEICHOR
Condition: Clinical Stage Ii Gastroesophageal Junction Adenocarcinoma A Synced from ClinicalTrials.gov · August 04, 2026

Recruiting studies: Clinical Stage Ii Gastroesophageal Junction Adenocarcinoma A

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced
NA · 1 location(s) · Fudan University · NCT06158919A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastr
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06423885XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
Phase 1/Phase 2 · 2 location(s) · West China Hospital · NCT06742411Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06808971Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi
Phase 2/Phase 3 · 10 location(s) · Beijing Biostar Pharmaceuticals Co., Ltd. · NCT06841679Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal J
Phase 2 · 1 location(s) · Zekuan Xu · NCT06461910A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT04982276Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06947291Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fet
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07289997NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04615013Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07277439Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastri
Phase 2 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07483567Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT04908566A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesoph
Phase 2 · 1 location(s) · Fudan University · NCT07492615Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07325630Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocar
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06163729Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanc
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT05651594
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.